MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317755 | Name: Dronedarone HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dronedarone is an antiarrhythmic, acting as a multichannel blocker. Dronedarone inhibits multiple outward potassium currents and reduces inward rapid Na current and L-type Ca channels. Dronedarone has been termed a "multichannel blocker".[citation needed] However, it is unclear which channel(s) play a pivotal role in its success. Thus, dronedarone's actions at the cellular level are controversial, with most studies suggesting an inhibition in multiple outward potassium currents including rapid delayed rectifier, slow delayed rectifier and ACh-activated inward rectifier. It is also believed to reduce inward rapid Na current and L-type Ca channels.

Chemical Structure

Dronedarone HCl
Dronedarone HCl
CAS#141625-93-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 317755

Name: Dronedarone HCl

CAS#: 141625-93-6 (HCl)

Chemical Formula: C31H45ClN2O5S

Exact Mass: 0.0000

Molecular Weight: 593.22

Elemental Analysis: C, 62.76; H, 7.65; Cl, 5.98; N, 4.72; O, 13.49; S, 5.41

Price and Availability

Size Price Availability Quantity
100mg USD 150.00 2 Weeks
500mg USD 350.00 2 Weeks
1g USD 550.00 2 Weeks
2g USD 750.00 2 Weeks
5g USD 1,450.00 2 Weeks
10g USD 2,050.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
141626-36-0 (free base) 141625-93-6 (HCl)
Synonym
Dronedarone Hydrochloride; Dronedarone HCl; Multaq; SR-33589; SR33589; SR 33589; SR-33589B;
IUPAC/Chemical Name
N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide;hydrochloride
InChi Key
DWKVCQXJYURSIQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H44N2O5S.ClH/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3;/h13-18,23,32H,5-12,19-22H2,1-4H3;1H
SMILES Code
CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Dronedarone Hydrochloride is a non-iodinated amiodarone derivative that inhibits Na+, K+ and Ca2+ currents.
In vitro activity:
Dronedarone also inhibited the GTP-gamma-S induced K+ current by 28% and 58% at 0.01 and 0.1 microM, respectively. These data suggest that dronedarone inhibits I(K(ACh)) by depressing the function of K(ACh) channel itself or associated GTP-binding proteins. Reference: J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5. https://pubmed.ncbi.nlm.nih.gov/11117382/
In vivo activity:
Dronedarone inhibited carotid artery thrombus formation in vivo (P < 0.05). Thrombin- and collagen-induced platelet aggregation was impaired in dronedarone-treated mice (P < 0.05), and expression of plasminogen activator inhibitor-1 (PAI1), an inhibitor of the fibrinolytic system, was reduced in the arterial wall (P < 0.05). Dronedarone inhibits thrombus formation in vivo through inhibition of platelet aggregation and PAI1 expression. Reference: Basic Res Cardiol. 2012 Nov;107(6):302. https://pubmed.ncbi.nlm.nih.gov/23052639/
Solvent mg/mL mM comments
Solubility
DMSO 46.7 78.67
Ethanol 22.5 37.93
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 593.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Guillemare E, Marion A, Nisato D, Gautier P. Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5. doi: 10.1097/00005344-200012000-00017. PMID: 11117382. 2. Altomare C, Barbuti A, Viscomi C, Baruscotti M, DiFrancesco D. Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. Br J Pharmacol. 2000 Jul;130(6):1315-20. doi: 10.1038/sj.bjp.0703446. PMID: 10903971; PMCID: PMC1572204. 3. Breitenstein A, Sluka SH, Akhmedov A, Stivala S, Steffel J, Camici GG, Riem HH, Beer HJ, Studt JD, Duru F, Luscher TF, Tanner FC. Dronedarone reduces arterial thrombus formation. Basic Res Cardiol. 2012 Nov;107(6):302. doi: 10.1007/s00395-012-0302-4. Epub 2012 Sep 29. PMID: 23052639. 4. Bogdan R, Goegelein H, Ruetten H. Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn Schmiedebergs Arch Pharmacol. 2011 Apr;383(4):347-56. doi: 10.1007/s00210-011-0599-9. Epub 2011 Jan 29. PMID: 21279331.
In vitro protocol:
1. Guillemare E, Marion A, Nisato D, Gautier P. Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5. doi: 10.1097/00005344-200012000-00017. PMID: 11117382. 2. Altomare C, Barbuti A, Viscomi C, Baruscotti M, DiFrancesco D. Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. Br J Pharmacol. 2000 Jul;130(6):1315-20. doi: 10.1038/sj.bjp.0703446. PMID: 10903971; PMCID: PMC1572204.
In vivo protocol:
1. Breitenstein A, Sluka SH, Akhmedov A, Stivala S, Steffel J, Camici GG, Riem HH, Beer HJ, Studt JD, Duru F, Luscher TF, Tanner FC. Dronedarone reduces arterial thrombus formation. Basic Res Cardiol. 2012 Nov;107(6):302. doi: 10.1007/s00395-012-0302-4. Epub 2012 Sep 29. PMID: 23052639. 2. Bogdan R, Goegelein H, Ruetten H. Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn Schmiedebergs Arch Pharmacol. 2011 Apr;383(4):347-56. doi: 10.1007/s00210-011-0599-9. Epub 2011 Jan 29. PMID: 21279331.
1: Tamargo J, López-Farré A, Caballero R, Delpón E. Dronedarone. Drugs Today (Barc). 2011 Feb;47(2):109-33. doi: 10.1358/dot.2011.47.2.1545699. PMID: 21431100. 2: Hoy SM, Keam SJ. Dronedarone. Drugs. 2009 Aug 20;69(12):1647-63. doi: 10.2165/11200820-000000000-00000. PMID: 19678715. 3: Patel C, Yan GX, Kowey PR. Dronedarone. Circulation. 2009 Aug 18;120(7):636-44. doi: 10.1161/CIRCULATIONAHA.109.858027. PMID: 19687370. 4: Gonska BD. Dronedaron [Dronedarone]. Herzschrittmacherther Elektrophysiol. 2010 Dec;21(4):244-7. German. doi: 10.1007/s00399-010-0092-z. PMID: 21104259. 5: Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M. Dronedarone: an overview. Ann Med. 2012 Feb;44(1):60-72. doi: 10.3109/07853890.2011.594808. Epub 2011 Jul 11. PMID: 21745093. 6: Boriani G, Blomström-Lundqvist C, Hohnloser SH, Bergfeldt L, Botto GL, Capucci A, Lozano IF, Goette A, Israel CW, Merino JL, Camm AJ. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace. 2019 Dec 1;21(12):1764-1775. doi: 10.1093/europace/euz193. PMID: 31324921. 7: Selvaraj V, Johnson KG. Dronedarone-induced optic neuropathy. Int J Cardiol. 2013 Jul 15;167(1):e8-9. doi: 10.1016/j.ijcard.2013.01.019. Epub 2013 Feb 8. PMID: 23398830. 8: Tadros R, Nattel S, Andrade JG. Dronedarone: Basic Pharmacology and Clinical Use. Card Electrophysiol Clin. 2016 Jun;8(2):453-65. doi: 10.1016/j.ccep.2016.02.008. Epub 2016 Mar 19. PMID: 27261834. 9: Vamos M, Hohnloser SH. Amiodarone and dronedarone: An update. Trends Cardiovasc Med. 2016 Oct;26(7):597-602. doi: 10.1016/j.tcm.2016.03.014. Epub 2016 Apr 4. PMID: 27155812. 10: Hughes PJ, Freeman MK, Cohenour FV, Price EM. Dronedarone: an alternative to amiodarone? Consult Pharm. 2010 Sep;25(9):555-69. doi: 10.4140/TCP.n.2010.555. PMID: 20876046. 11: Page RL, Hamad B, Kirkpatrick P. Dronedarone. Nat Rev Drug Discov. 2009 Oct;8(10):769-70. doi: 10.1038/nrd2998. PMID: 19794441. 12: Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs. 2004 Apr;13(4):415-26. doi: 10.1517/13543784.13.4.415. PMID: 15102590. 13: Oyetayo OO, Rogers CE, Hofmann PO. Dronedarone: a new antiarrhythmic agent. Pharmacotherapy. 2010 Sep;30(9):904-15. doi: 10.1592/phco.30.9.904. PMID: 20795846. 14: Marzocchi M, Lombardi F. Dronedarone for atrial fibrillation therapy. Expert Rev Cardiovasc Ther. 2011 Jun;9(6):675-83. doi: 10.1586/erc.11.58. PMID: 21714598. 15: Singh JP, Blomström-Lundqvist C, Turakhia MP, Camm AJ, Fazeli MS, Kreidieh B, Crotty C, Kowey PR. Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis. Clin Cardiol. 2023 Jun;46(6):589-597. doi: 10.1002/clc.24011. Epub 2023 Apr 6. PMID: 37025083; PMCID: PMC10270269. 16: Wharton JM, Piccini JP, Koren A, Huse S, Ronk CJ. Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc. 2022 Feb;11(3):e020506. doi: 10.1161/JAHA.120.020506. Epub 2022 Jan 21. Erratum in: J Am Heart Assoc. 2022 May 17;11(10):e020803. PMID: 35060388; PMCID: PMC9238499. 17: Clem JR, Farver DK, Fischer JR, Johnson TJ. Dronedarone: a safety comparison to amiodarone. Curr Drug Saf. 2010 Jul 2;5(3):251-6. doi: 10.2174/157488610791698280. PMID: 20210734. 18: Schafer JA, Kjesbo NK, Gleason PP. Dronedarone: current evidence and future questions. Cardiovasc Ther. 2010 Spring;28(1):38-47. doi: 10.1111/j.1755-5922.2009.00112.x. PMID: 20074258. 19: Tarapués M, Cereza G, Figueras A. Dronedarone and renal impairment: evaluation of Spanish postmarketing reports and review of literature. Expert Opin Drug Saf. 2015 Jun;14(6):807-13. doi: 10.1517/14740338.2015.1036857. Epub 2015 May 12. PMID: 25967281. 20: McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N, Palmer S. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. 2012 Jan;30(1):35-46. doi: 10.2165/11594280-000000000-00000. PMID: 22136303.